about
Heart Disease in Women: Unappreciated Challenges, GPER as a New TargetNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionPCSK9 and triglyceride-rich lipoprotein metabolismTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainNew Era of Lipid-Lowering DrugsPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraPCSK6-mediated corin activation is essential for normal blood pressureLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.Atherogenesis and metabolic dysregulation in LDL receptor-knockout rats.PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shot.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?PCSK9 antibodies for the treatment of hypercholesterolemiaAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFROn the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.The Bottleneck in Genetic Testing.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaPlasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Mechanism of Fine-tuning pH Sensors in Proprotein Convertases: IDENTIFICATION OF A pH-SENSING HISTIDINE PAIR IN THE PROPEPTIDE OF PROPROTEIN CONVERTASE 1/3.New insights of altered lipid profile in Fragile X Syndrome.Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.The enigmatic role of sortilin in lipoprotein metabolism.Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placeboHuman PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.The Case of "Missing Causal Genes" and the Practice of Medicine: A Sherlock Holmes Approach of Deductive Reasoning.Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering StrategiesEfficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody.Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients With Stable Coronary Artery Disease: A Prospective Observational Cohort Study.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.PCSK9 targets important for lipid metabolism
P2860
Q26746957-EE751EA1-C484-47BF-9B28-A18A83EE49F3Q26783407-1E508ED9-ABD2-4443-A910-60BA8F862D1BQ26796287-0E2D623C-2EAD-44AA-B7E0-6543D0208B10Q27339783-3884808E-262D-448A-828F-245615FE920BQ28072298-3F95091D-F3E2-43C6-AC64-22AF438593D8Q28073656-FFBC6F00-1088-4702-BBF1-764A3B9CFF10Q28266080-9061C958-882C-4228-879D-AE923FDE8E58Q30248925-1EF8B71A-A0D9-4162-9F15-61B5077E9058Q30968588-89D0BCD3-9535-42F3-AB22-D66360E53D70Q32179917-B3548DFF-8A37-4BCA-B029-07B972193C8CQ33599961-10D77AF7-2764-461E-AE73-5DAEA268D9F9Q33625574-CC584F2A-1C97-4660-B2E2-60BB7C4C5937Q34063943-B44599A9-3CA1-4DBF-ACD4-C46F83ACA8ADQ34355679-959A4120-48A0-4822-B3D5-64FE4786B0D6Q34397436-6D74712E-F216-4ACD-93CE-1A1AF3A96756Q34774969-2F64A0FC-095C-4A15-BE86-112AEF068B8EQ35836143-4324F64F-1222-452B-BB3A-6250F4D2D44EQ35883857-9BEAA74F-4035-4076-BB64-F0B8C0E28475Q35901123-D61DB7EE-CD31-45D0-8B9A-3C2D7F87101CQ36035643-F72C1E9D-A3E2-43A6-AF7E-0252818CB3DAQ36077789-73DCA6A2-F6A6-47BC-AEA4-AB099739142AQ36130225-40DE1368-460B-4FA1-B729-F5B682F697D6Q36278291-155644FD-9F59-49F7-AE2F-5895671628B5Q36281706-69C4C4D5-3714-4C39-A7CE-B3B6402E4F2AQ36281710-8681825F-3EDD-4156-A85D-7F195076ACEFQ36320196-87226A53-C127-4B8A-9669-ABCC9C80CE83Q36411986-D947BF5B-D437-4441-8303-53FDA8A29408Q36496747-5A87DE69-E887-42C4-8592-DE58D64E4F3FQ36506609-FA309690-E928-4185-88A5-9D7F6FF215ECQ36577724-0B1CC24F-9597-440F-9570-32E5E38EB54FQ36812669-83CF5054-81BB-4BDD-B7A5-12037569C3E0Q37041773-940749AC-11B4-43E4-BDC9-3EA615EE5EE8Q37076167-6D8B0E5F-69A3-4D9A-9E1C-AEE0F4D269DBQ37364393-23F77857-DC37-4264-AF6F-45892E48C45BQ37397710-A3AACA44-7972-465C-A165-8A2051CDC57AQ37466779-0691E96D-8315-4B9A-BBDB-EBB364B2ED93Q37603961-8ABEB676-027D-470B-B011-BAE71C544886Q37624278-23370281-E815-44B0-8816-83DCB5F6480DQ37688760-4D93A3F4-D598-42A8-811D-9694696D170EQ37703261-DC468465-7B24-48BB-AC2A-DC30D615A4EE
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
PCSK9: a key modulator of cardiovascular health
@ast
PCSK9: a key modulator of cardiovascular health
@en
PCSK9: a key modulator of cardiovascular health
@nl
type
label
PCSK9: a key modulator of cardiovascular health
@ast
PCSK9: a key modulator of cardiovascular health
@en
PCSK9: a key modulator of cardiovascular health
@nl
prefLabel
PCSK9: a key modulator of cardiovascular health
@ast
PCSK9: a key modulator of cardiovascular health
@en
PCSK9: a key modulator of cardiovascular health
@nl
P3181
P1433
P1476
PCSK9: a key modulator of cardiovascular health
@en
P2093
Majambu Mbikay
Zuhier Awan
P304
P3181
P356
10.1161/CIRCRESAHA.114.301621
P407
P577
2014-03-01T00:00:00Z